IIT Bombay graduates-founded startup Entvin AI raises $500,000 from Y Combinator

Entvin AI, a startup founded by three IIT Bombay graduates, has launched out of beta and announced that it raised $500,000 in its first funding round from Y Combinator.

Entvin AI, which provides specialized AI solutions for pharmaceutical and life sciences companies worldwide, plans to expand its AI capabilities and accelerate customer acquisition among mid-to-large pharmaceutical companies globally.

Who are the founders?

Founded by Sanskar Jain, Hemant Phalak and Rishabh Arya, Entvin AI has developed an AI platform that streamlines the notoriously time-consuming, resource-intensive and complex FDA drug approval process. 

The startup reports early success with enterprise pilot customers, demonstrating that its AI solution can save hundreds of hours for regulatory and scientific teams while improving compliance accuracy, a critical factor in an industry where regulatory missteps can cost millions.

With the FDA drug approval process often taking years and costing millions, any inefficiency can significantly impact a company's bottom line and delay potentially life-saving treatments from reaching patients. Entvin AI aims to mitigate this risk through a specialized platform built specifically for regulatory teams.

The startup's platform directly targets this bottleneck by automating document drafting, compliance verification, and regulatory monitoring tasks that traditionally consume thousands of hours of highly skilled professional time. Its technical architecture leverages large language models specifically fine-tuned for regulatory documentation and FDA compliance requirements, the release notes.

Leadership comments

Sanskar Jain, Co-Founder & CEO of Entvin, said, "We identified a significant opportunity to transform how life sciences companies navigate regulatory requirements. Regulatory professionals spend countless hours on documentation, compliance checks, and staying updated with constantly evolving FDA guidelines. Our AI agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens."

Hemant Phalak, Co-Founder & CPO, said, "At Entvin, our AI agents seamlessly integrate into existing workflows to enhance efficiency and accelerate decision-making. Our platform doesn't just organize information - it actively identifies compliance gaps, automates repetitive documentation tasks, and provides regulatory teams with actionable insights in real time. This helps life science companies navigate the approval process with unprecedented efficiency while maintaining trust, reliability and seamless integration."

Rishabh Arya, Co-Founder & CTO of Entvin, said, "We've developed an AI system that deeply understands the complex language of FDA regulations and can process massive volumes of regulatory documentation. Our architecture is enterprise-grade, designed to meet the highest compliance standards required by pharmaceutical companies like SOC 2, ISO 2700."